Aripiprazole Effects on Alcohol Drinking and Craving
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
| Condition | Intervention | Phase |
|---|---|---|
|
Alcohol Dependence |
Drug: Aripiprazole Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication |
- total number of drinks per day during natural (usual environment) conditions [ Time Frame: 5-day observation period ] [ Designated as safety issue: No ]"Natural" alcohol consumption period -- drinks per day consumed during the 5-day observation period
- Total number of drinks under controlled conditions (bar lab) [ Time Frame: 2 hours during the alcohol challenge procedure ] [ Designated as safety issue: No ]Limited access alcohol consumption paradigm -- Total number of drinks consumed
| Estimated Enrollment: | 120 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Aripiprazole
Medication
|
Drug: Aripiprazole
Aripiprazole(up to 15 mg/day) for 8 days
Other Name: Abilify
|
| Placebo Comparator: Sugar pill |
Drug: Placebo
Placebo to match active drug Aripiprazole for 8 days
|
Detailed Description:
Non-treatment seeking individuals meeting criteria for alcohol dependence (N=120) will be recruited through advertisement and paid for their participation. Subjects will have blood drawn for DNA analysis of various brain dopamine system genes. Alcoholics, after baseline evaluation, will be assigned through urn randomization to one of two experimental groups, depending on their baseline level of impulsivity, in which they will receive either aripiprazole (up to 15 mg/day) or an identical placebo. Subjects will take the study drug or placebo for 8 days (day 1-6 being the natural observation period). After a minimum of 24 hours of abstinence from alcohol (day 7-8) they will undergo an alcohol administration (priming dose) and motivated free choice drinking procedure (on day 8). Alcoholic subjects will receive a brief counseling session at the end of the study to enhance their awareness of problem drinking and to motivate them to seek treatment. Referral for treatment will be offered.
Each subject will undergo a functional MRI (functional magnetic resonance imaging) brain scan with cue stimulation on day 7, on the evening before the alcohol administration paradigm. fMRI brain imaging technology will be used to determine if alcoholics treated with aripiprazole differ in alcohol cue-induced activity in the nucleus accumbens. It is hypothesized that aripiprazole will reduce nucleus accumbens activation to alcohol cues compared to placebo.
Whether dopamine system genetic differences will be predict drinking, nucleus accumbens activity, and aripiprazole response will be explored.
Eligibility| Ages Eligible for Study: | 21 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 21 - 40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
- Meets the DSM IV criteria for current alcohol dependence including criterion 3 and/or 4 "loss of control over drinking" or "the inability to cut-down or stop drinking".
- Currently not engaged in, and does not want treatment for, alcohol related problems.
- Able to read and understand questionnaires and informed consent.
- Lives within 50 miles of the study site.
- Able to maintain abstinence for two days (without the aid of detoxification medications) as determined by self report and breathalyzer measurements.
Inclusion for fMRI Imaging:
- Does not have metal objects in the head/neck.
- Does not have a history of claustrophobia leading to significant clinical anxiety symptoms.
Exclusion Criteria:
- Currently meets DSM IV criteria for any other psychoactive substance dependence disorder.
- Any psychoactive substance use (except marijuana and nicotine) within the last 30 days by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine THC levels.
- Meets DSM IV criteria for current axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, dissociate disorders and eating disorders, any other psychotic disorder or organic mental disorder.
- Has current suicidal ideation or homicidal ideation.
- Need for maintenance or acute treatment with any psychoactive medication including anti-seizure medications and medications for ADHD.
- Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
- Clinically significant medical problems such as cardiovascular, renal, GI, or endocrine problems that would impair participation or limit medication ingestion.
- Past history of alcohol related medical illness such as gastrointestinal bleeding, pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis.
- Hepatocellular disease indicated by elevations of SGPT (ALT) or SGOT (AST) greater than 2.5 times normal at screening.
- Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are not using a reliable form of birth control.
- Has current charges pending for a violent crime (not including DUI (Driving Under Intoxication) related offenses).
- Does not have a stable living situation.
Contacts and Locations| Contact: Konstantin F. Voronin, MD, PhD | 843-792-4887 | voronin@musc.edu |
| Contact: Raymond F. Anton, MD | 843-792-1226 | antonr@musc.edu |
| United States, South Carolina | |
| Medical University of South Carolina, Institute of Psychiatry, Center for Drug and Alcohol Programs | Recruiting |
| Charleston, South Carolina, United States, 29425 | |
| Contact: Konstantin E. Voronin, MD, PhD 843-792-4887 voronin@musc.edu | |
| Principal Investigator: | Raymond Anton, M.D. | Medical University of South Carolian |
More Information
Additional Information:
No publications provided
| Responsible Party: | Raymond F. Anton, Professor, Medical University of South Carolina |
| ClinicalTrials.gov Identifier: | NCT01292057 History of Changes |
| Other Study ID Numbers: | NIH P50 AA010761, P50AA010761 |
| Study First Received: | February 7, 2011 |
| Last Updated: | April 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Medical University of South Carolina:
|
Alcohol Aripiprazole Impulsivity Alcoholism drinking |
treatment craving brain imaging genetics |
Additional relevant MeSH terms:
|
Alcoholism Alcohol-Related Disorders Substance-Related Disorders Mental Disorders Aripiprazole Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 22, 2013